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Abstract
Background: Concern exists that frequent use of topically-applied fusidic acid (FA) and chlorhexidine (CHX) for
canine pyoderma is driving clinically relevant resistance, despite rare description of FA and CHX genetic resistance
determinants in canine-derived staphylococci. This study aimed to determine minimum inhibitory concentrations
(MICs) and investigate presence of putative resistance determinants for FA and CHX in canine-derived methicillin-
resistant (MR) and -susceptible (MS) staphylococci. Plasmid-mediated resistance genes (fusB, fusC, fusD, qacA/B, smr;
PCR) and MICs (agar dilution) of FA and CHX were investigated in 578 staphylococci (50 MR S. aureus [SA], 50 MSSA,
259 MR S. pseudintermedius [SP], 219 MSSP) from Finland, U.S.A., North (NUK) and South-East U.K. (SEUK) and
Germany. In all isolates with FA MIC ≥64 mg/L (n = 27) fusA and fusE were amplified and sequenced.
Results: FA resistance determinants (fusA mutations n = 24, fusB n = 2, fusC n = 36) were found in isolates from all
countries bar U.S.A. and correlated with higher MICs (≥1 mg/L), although 4 SP isolates had MICs of 0.06 mg/L
despite carrying fusC. CHX MICs did not correlate with qacA/B (n = 2) and smr (n = 5), which were found in SEUK SA,
and SP from NUK and U.S.A.
Conclusions: Increased FA MICs were frequently associated with fusA mutations and fusC, and this is the first
account of fusB in SP. Despite novel description of qacA/B in SP, gene presence did not correlate with CHX MIC.
Selection pressure from clinical use might increase prevalence of these genetic determinants, but clinical
significance remains uncertain in relation to high skin concentrations achieved by topical therapy.
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Background
Coagulase-positive staphylococci, primarily Staphylococcus
pseudintermedius and less often S. aureus and S. schleiferi,
are the predominant pathogens in canine superficial pyo-
derma [1]. The emergence of methicillin-resistant strains of
S. pseudintermedius (MRSP), that are usually resistant to
most or all available licensed systemic veterinary antimicro-
bials [2, 3], has increased interest in the use of topical ther-
apy [4], most commonly with products that contain fusidic
acid or chlorhexidine [5]. These same antimicrobials are
used topically in human medicine, but in people fusidic
acid is also used systemically as a last line treatment option
for bacteraemia caused by methicillin-resistant S. aureus
(MRSA) [6].
Infections caused by methicillin-susceptible (MS) and
MRSP have been documented in humans [7–10], and
zoonotic transmission of MSSP and MRSP has been in-
ferred by the isolation of genetically identical MRSP iso-
lates from pet dogs and their infected human owners
[11]. Similarly, occasional human nasal carriage of MSSP
and even MRSP has been described [12–14], again with
indistinguishable pulsed-field gel electrophoresis (PFGE)
patterns to those carried by in-contact pet dogs [15, 16].
Topical therapy with fusidic acid is common in human
medicine for staphylococcal skin infections and is also rec-
ommended [17] and used in dogs with skin infections, at
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least in European countries but not in the U.S.A. Chlor-
hexidine is used worldwide as a disinfectant and antisep-
tic, and in topical antibacterial products for dogs. Whilst
topical antibacterial therapy is recommended as an alter-
native to systemic treatment [4] in order to reduce selec-
tion pressure on pathogens, there are concerns over
reduced phenotypic susceptibility to these agents [18, 19].
In New Zealand, clonal expansion of fusidic acid-resistant
S. aureus (based on disk diffusion testing) was reported
concurrently with a significant increase in national dispens-
ing of topical fusidic acid products for humans [20]. By
contrast, the prevalence of phenotypic resistance to fusidic
acid (minimum inhibitory concentration [MIC] ≥ 1mg/L
determined using VITEK 2) [21] increased amongst MRSA
in the U.K. despite stable (2002–2009) and decreasing
(2009–2013) fusidic acid sales [22]. Reduced susceptibility
of MRSA to chlorhexidine following increased antiseptic
use was demonstrated in human hospitals [19, 23, 24]; the
presence of genetic characteristics thought to be related to
reduced chlorhexidine susceptibility has also been impli-
cated in failure of decolonisation strategies [25].
The acquired resistance genes fusB [26–28], fusC [27–29]
and fusD [28, 29], most commonly carried on plasmids,
and chromosomal mutations in fusA [27, 28, 30, 31] and
fusE [28, 31] have been associated with reduced susceptibil-
ity to fusidic acid in S. aureus. Geographical variation in the
presence of these genes in phenotypically fusidic
acid-resistant S. aureus derived from humans, defined by
clinical breakpoints, has been described [28, 32–34]. In S.
pseudintermedius, there is one publication that describes
fusA mutations conferring fusidic acid resistance in a single
isolate [35], and only two isolates of S. (pseud)intermedius
have been shown to carry fusC [29], despite widespread li-
censing and marketing of fusidic acid products for topical
use in small animal veterinary practice in Europe during
the past four decades.
Plasmid-derived qacA/B and smr have an uncertain
correlation with reduced susceptibility to chlorhexidine
amongst staphylococci [36–41]. Transfer of qacA/B by
transduction between isolates of S. aureus has been de-
scribed, although the effect of this transfer on suscepti-
bility to chlorhexidine was not assessed [42]. Whether
transfer of resistance genes can occur between S. pseu-
dintermedius and S. aureus still remains unclear but evi-
dence for such transfer between staphylococcal species
exists [43], most notably of the SCCmec (predominantly
type IV) which encodes methicillin resistance and is be-
lieved to have originated in coagulase-negative staphylo-
cocci [44–47]. An increase in the prevalence of resistance
genes in canine-derived staphylococci due to veterinary
use of topically-applied antimicrobials could become of
concern to veterinarians if clinical failure occurred. Fur-
thermore, there could be implications for both human
and canine health through either transfer of resistant
strains between hosts, or of genetic material to susceptible
bacterial species. This study investigated the association
between resistance genes and MICs of fusidic acid and
chlorhexidine in canine-derived S. pseudintermedius and
S. aureus in a large collection of isolates obtained from
wide geographical areas.
Results
The MICs (new and previously determined), MIC50,
MIC90 values and comparisons between regional groups
are detailed in Fig. 1 and Tables 1 and 2.
The MICs of fusidic acid specifically determined for this
study for S. pseudintermedius (n = 339) from NUK, Finland
and the U.S.A ranged from 0.03 to > 64mg/L. In the 40
Finnish FA-R MRSP the lowest MIC was 4mg/L. Of the
remaining 299 isolates, 76 had MIC ≥1mg/L (43 NUK, 31
Finland, 2U.S.A) while 223 isolates were phenotypically fusi-
dic acid-susceptible based on EUCAST breakpoints [21]
(Table 1). The MICs of reference isolates were low (ATCC®
25923™ and LMG 22219, 0.06mg/L; ATCC® 29663™, 0.03
mg/L), consistent with previous reports [48, 49]. Chlorhexi-
dine MICs of Finnish and U.S.A. isolates (n = 200) ranged
from 0.25 to 4mg/L; 196 isolates had MICs of 0.5 or 1mg/L
(1 Finnish MRSP, 0.25mg/L; 1U.S.A. MSSP, 2mg/L; 1
Finnish MRSP and 1U.S.A. MSSP, 4mg/L; Table 2). The
MICs for fusidic acid and chlorhexidine did not differ be-
tween MRSP and MSSP within groups of isolates from each
country (fusidic acid U.S.A., Germany, SEUK P = 1.000,
Finland P = 0.408; chlorhexidine U.S.A, Finland, SEUK
P = 1.000, Germany P = 0.152) except in the NUK
(P < 0.005 for both fusidic acid and chlorhexidine).
Twenty-seven of all 578 staphylococci, had fusidic acid
MIC ≥64mg/L and thus underwent fusA and fusE sequen-
cing (5 MRSA SEUK, 4 MSSP NUK, 4 MRSP NUK, 1
MRSP SEUK, 1 Finnish MRSP, 12 Finnish FA-R MRSP).
All eight internal primers designed to sequence the 2100
bp product of fusA aligned to S. pseudintermedius. Al-
though two primers (FusA_Int_D_F and FusA_Int_F_R;
Table 3) did not align with S. aureus isolates, the whole
gene sequence was obtained using the remaining six
primers in 3 / 5 MRSA isolates. In the remaining two
MRSA isolates, mutation analyses were prevented by fail-
ure to amplify fusA.
Of the remaining 25 isolates with an MIC ≥64mg/L (3
MRSA, 4 MSSP NUK, 4 MRSP NUK, 1 MRSP SEUK, 1
Finnish MRSP, 12 Finnish FA-R MRSP), 24 had at least
one fusA mutation (Table 4); one MRSA isolate had none.
All mutations observed represented non-conservative sub-
stitutions (Table 4). No fusE mutations were detected in
any of the tested isolates (fusidic acid MIC ≥64mg/L).
Of the plasmid-mediated fusidic acid resistance genes,
fusB and fusC were detected in the collection but fusD
was not (Table 1). In S. pseudintermedius, fusB was de-
tected in 2 isolates (5%) of the Finnish FA-R MRSP; fusB
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was not detected in isolates from any other region, nor
in S. aureus. In Finnish S. pseudintermedius, fusC was
quite regularly detected (13/40 FA-R MRSP, 9/49 MRSP,
5/50 MSSP), as well as being found in 7/49 NUK MRSP.
It was not detected in S. pseudintermedius from any
other region. In S. aureus, fusC was detected in 2/50
SEUK MSSA.
Both fusB carrying isolates had MICs of 8mg/L (Table 1).
In 32 isolates (89%) carrying fusC, the fusidic acid MIC was
4–16mg/L (Table 1). However, the other four isolates car-
rying fusC (1 NUK MRSP, 2 Finnish MRSP, 1 Finnish
MSSP) had a fusidic acid-sensitive phenotype (MIC = 0.06
mg/L) (Table 1).
The only MRSA isolate with a fusidic acid MIC of 64
mg/L that had no mutation in either fusA or fusE, did
not carry fusB, fusC or fusD either. Similarly, 51 isolates
(1 MSSA, 34 MRSP, 16 MSSP) with ‘low-level’ fusidic
acid resistance (MIC 4–16mg/L) [28] did not carry fusB,
fusC or fusD.
The chlorhexidine resistance determinants qacA/B
and smr were not detected in any isolates from
Germany or Finland, nor in S. pseudintermedius from
SEUK (Table 2). In S. pseudintermedius from the
U.S.A., 3/50 MRSP isolates and 1/51 MSSP isolates car-
ried the smr gene; 1 NUK MSSP isolate (out of 50) car-
ried qacA/B. In S. aureus (all SEUK), 1 MSSA carried
qacA/B and 1 carried smr. Presence of smr related to
chlorhexidine MICs of 0.5–4 mg/L and presence of
qacA/B related to chlorhexidine MICs of 2–4 mg/L
(Table 2).
No single isolate carried more than one of the resist-
ance determinants investigated.
a
b
Fig. 1 Comparative statistical overview of MIC of a) fusidic acid and b) chlorhexidine for canine-derived S. pseudintermedius from different
geographical regions. P values stated; P < 0.05 indicates significance, depicted in bold. SEUK: South-East U.K.; NUK: North U.K
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Table 1 Minimum inhibitory concentrations (MICs) of fusidic acid determined by agar dilution, and presence of resistance
determinants, for canine-derived Staphylococcus pseudintermedius and S. aureus isolates (n = 578) from Finland, the U.S.A., North U.K.
(NUK), South-East U.K. (SEUK) and Germany
Country Bacterial
Type
n Fusidic acid MIC (mg/L) MIC50 MIC90
≤0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >64 (mg/L) (mg/L)
Finland MRSP 49 0 0 28 n =
2 fusC
0 0 0 0 3 5 n = 4
fusC
4 n = 2 fusC 8 n =
1 fusC
0 1 n = 1
fusA
0 0.06 16
FA-R
MRSP
40 0 0 0 0 0 0 0 0 13 n =
12 fusC
10 n = 1 fusC
n = 2 fusB
5 0 12 n =
12 fusA
0 8 64
MSSP 50 0 1 38 n =
1 fusC
1 0 0 0 0 0 7 n = 3 fusC 3 n =
1 fusC
0 0 0 0.06 8
U.S.A. MRSP 50 0 2 38 10 0 0 0 0 0 0 0 0 0 0 0.06 0.125
MSSP 51 0 0 47 2 0 0 0 0 2 0 0 0 0 0 0.06 0.06
NUK MRSP 49 0 0 14 n =
1 fusC
4 0 0 0 14 2 n = 1
fusC
10 n = 5 fusC 0 0 4 n = 4
fusA
1 2 64
MSSP 50 0 1 37 0 0 0 1 0 1 5 1 0 2 n = 2
fusA
2 n =
2 fusA
0.06 8
SEUKa MRSP 47 22 1 12 3 0 0 1 2 4 0 1 0 1 n = 1
fusA
0 0.06 4
MSSP 44 19 5 14 1 0 0 2 2 0 1 0 0 0 0 0.03 1
MRSA 50 8 34 0 0 3 0 0 0 0 0 0 0 1 4 n =
2 fusA
0.03 0.25
MSSA 50 24 13 0 0 1 1 6 2 2 n = 2
fusC
0 1 0 0 0 0.03 1
Germanya MRSP 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.015 <0.015
MSSP 21 0 0 0 0 0 0 0 3 0 0 0 0 0 0 <0.015 <0.015
EUCAST breakpoint for fusidic acid for staphylococci is 1 mg/L; (reference [62]).
MRSP methicillin-resistant Staphylococcus pseudintermedius, FA-R fusidic acid-resistant, MSSP methicillin-sensitive S. pseudintermedius, NUK North U.K., SEUK South-East
U.K, MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus.
aMICs determined as part of previous study by the authors (reference [52])
Table 2 Minimum inhibitory concentrations (MICs) of chlorhexidine determined by agar dilution, and presence of resistance
determinants, for canine-derived Staphylococcus pseudintermedius and S. aureus isolates (n = 538) from Finland, the U.S.A., North U.K.
(NUK), South-East U.K. (SEUK) and Germany
Country Bacterial
Type
n Chlorhexidine MIC (mg/L) MIC50 MIC90
0.125 0.25 0.5 1 2 4 8 16 mg/L mg/L
Finland MRSP 49 0 1 35 12 0 1 0 0 0.5 1
MSSP 50 0 0 38 12 0 0 0 0 0.5 1
U.S.A. MRSP 50 0 0 35 n = 2 smr 15 n = 1 smr 0 0 0 0 0.5 1
MSSP 51 0 0 45 n = 1 smr 4 1 1 0 0 0.5 1
NUKb MRSP 49 0 0 0 16 25 8 0 0 2 4
MSSP 50 0 0 0 36 14 n = 1 qacA/B 0 0 0 1 2
SEUKa MRSP 47 0 0 0 21 23 2 1 0 2 2
MSSP 44 0 0 1 22 17 2 2 0 1 2
MRSA 50 0 0 0 0 0 49 1 0 4 4
MSSA 50 0 0 1 22 22 5 n = 1 qacA/B n = 1 smr 0 0 2 2
Germanya MRSP 24 0 0 9 4 11 0 0 0 1 2
MSSP 24 0 0 11 13 0 0 0 0 1 1
MRSP methicillin-resistant Staphylococcus pseudintermedius, MSSP methicillin-sensitive S. pseudintermedius, NUK North U.K., SEUK South-East U.K, MRSA methicillin-
resistant S. aureus, MSSA methicillin-susceptible S. aureus.
aMICs determined as part of previous study by the authors (reference [52])
bMICs determined as part of previous study by the authors (reference [45])
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Discussion
The same acquired resistance genes (fusA mutations,
fusB, fusC, qacA/B and smr) that have been previously
described in human-derived S. aureus [32–34] were
found in canine-derived S. pseudintermedius and S. aur-
eus in this study. However, for some of these genes, evi-
dence of their association with increased fusidic acid and
chlorhexidine MICs remains inconclusive.
For S. aureus, chromosomal mutations in fusA have
been shown experimentally to elevate the MIC of fusidic
acid by up to 32-fold [30], causing ‘high-level’ fusidic
acid resistance in clinical isolates. The results from this
study now support a previous report on a single isolate
[35] that this is also the case for S. pseudintermedius, as
fusA mutations were detected in isolates from the SEUK
(MRSP), NUK (MRSP and MSSP) and Finland (MRSP).
Whether fusA mutations play a role in ‘low-level’ resist-
ance (MIC 4–16mg/L) [28] remains to be investigated,
particularly since there were 51 isolates with MICs com-
patible with ‘low-level’ resistance that did not carry
fusB-D [28]. Failure to amplify fusA in two MRSA iso-
lates might reflect mutation(s) at primer-binding sites;
this could be evaluated by whole genome sequencing.
The single canine-derived MRSP previously reported
with fusA mutations [35], showed substitutions at the
same three sites (V90I, A376V and I461V) as those
found in 20 of the 24 isolates with fusA mutations in this
study. A novel substitution at one of these sites (I461T),
likely related to reduced fusidic acid susceptibility, was
shown in MRSP from Finland, NUK and SEUK. The
other two amino acid substitutions found within fusA
during this study (V90I, A376V) were at positions that
are conserved between fusidic acid-susceptible S. aureus
and S. pseudintermedius, and mutations at these sites
have been previously described in European S. aureus
[27, 30, 32, 35]. Substitution at position 90 (V - > I) has
previously been shown to be unrelated to fusidic acid re-
sistance in S. pseudintermedius when found on its own
[35], and could have a compensatory effect to counteract
fitness cost associated with other mutations [50]. The
novel identification of the same mutations in three MSSP
isolates from the NUK could be due to loss of methicillin
resistance. This has been previously demonstrated in S.
aureus, due to fitness costs of carrying some SCCmec cas-
settes [51, 52], and is more likely than an identical set of
three single nucleotide polymorphisms arising in a separ-
ate lineage. Two canine-derived MRSA in this study had a
single mutation (L461K), which has been previously de-
scribed in human-derived S. aureus [32, 34], reflecting that
canine-derived MRSA isolates usually represent transfer
of successful human-hospital-associated lineages [53] into
the canine population.
This is the first description of fusB in S. pseudinterme-
dius resulting in ‘low-level’ fusidic acid resistance, in par-
allel to that previously described in S. aureus [28]. The
presence of fusB in a new staphylococcal species sug-
gests that there may have been genetic transfer of plas-
mids between staphylococci. Previous studies indicate
Table 3 Six custom primers designed and used for coverage of entire fusA PCR amplicon of staphylococci for Sanger sequencing,
alongside previously described forward and reverse primers (reference [34])
Primer Name Primer Sequence Forward / Reverse Base pair sequenced from
FusA_Int_A_F CGCCAACTCACGTGAAGAAA Forward 1077
FusA_Int_B_R ATTGACCACGACCACCAGAT Reverse 1516
FusA_Int_C_R TGCTTCACGTGCTTCTTCAG Reverse 639
FusA_Int_D_F CCAATCGGTGCTGAAGATGA Forward 493
FusA_Int_E_F ATCTGGTGGTCGTGGTCAAT Forward 1497
FusA_Int_F_R TGAGTTGGCTGTCATTTGTA Reverse 1086
FusA_Fa TTTACCCTGAGTGTGTTCT Forward 94
FusA_Ra TACATTTAAGCTCACCTTGT Reverse 2256
aPreviously described primers (reference [34])
Table 4 Mutation sites detected in fusA in two methicillin-resistant Staphylococcus aureus (MRSA), 18 methicillin-resistant S.
pseudintermedius (MRSP) and 4 methicillin-sensitive S. pseudintermedius (MSSP) isolates
Amino acid substitution Nucleotide substitution No. of isolates Fusidic acid MIC (mg/L)
L461K TTA - > AAA 2 (SEUK MRSA) 384a
I461K ATT - > AAA 1 (NUK MSSP) > 64
V90I / A376V / I461T GTA - > ATA / GCA - > GTA / ATT - > ACT 1 (NUK MSSP) > 64
20 (n = 12 FA-R Finland MRSP; n = 1 Finland MRSP,
n = 2 NUK MSSP, n = 4 NUK MRSP, n = 1 SEUK MRSP)
64
MIC minimum inhibitory concentration, SEUK South-East U.K, NUK North U.K.
aMIC determined as part of previous study (reference [52])
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that this may be a rare occurrence due to the difference
in restriction modification systems amongst staphylo-
cocci [35, 54]. However, the potential for further genetic
transfer of resistance determinants between S. aureus
and S. pseudintermedius, and amongst S. pseudinterme-
dius lineages, as previously shown for mecA amongst
staphylococci [44–47], highlights a risk to human health
from any increase in resistance in veterinary-derived
staphylococci and vice-versa. The presence of the same
plasmid-mediated resistance in different species could
also be evidence of a common ancestor for these genes
(such as fusB and fusC which show protein homology),
as has been previously described for the SCCmec of
staphylococci [46].
Whilst in the majority of cases the presence of fusC was
related to ‘low-level’ fusidic acid resistance, as described in
S. aureus carrying fusC [28], we report, for the first time,
four S. pseudintermedius isolates with a susceptible
phenotype (MIC = 0.06mg/L) despite presence of fusC.
This may reflect the fact that in previous studies, the pres-
ence of this gene has been investigated only in phenotyp-
ically fusidic acid-resistant (fusidic acid MIC ≥1mg/L)
isolates [32–34]. Phenotypic susceptibility in the presence
of fusC could be due to a chromosomal rather than a plas-
mid location of fusC [55], low copy number of fusC-con-
taining plasmids, or due to non-expression of the gene. It
may also question the relevance of fusC in reducing sus-
ceptibility to fusidic acid.
The low fusidic acid MICs in canine-derived S. pseudin-
termedius from the U.S.A. corresponds to its lack of use in
veterinary medicine, whereas MICs were higher in isolates
from the U.K and Finland which have had licensed fusidic
acid available to veterinarians for a number of years. This
mirrors the MICs of human-derived staphylococci which
tend to reflect fusidic acid use [32, 33]. Although MIC50
remained low in most regions tested (with the exception
of NUK MRSP), in our study the identification of genetic
resistance determinants correlated with raised MIC90 in
isolates from Finland and the U.K., matching the appar-
ently bimodal distribution of MICs above and below a ‘re-
sistance’ cut-off. The prevalence of fusB and fusC in the
European canine-derived staphylococci in this study is
broadly comparable to that seen in human-derived S. aur-
eus [32], with variation in gene presence between isolates
originating from differing European countries.
This study represents the first description of qacA/B and
corroborates previous reports of smr in S. pseudintermedius
[36], and supports recent reports of qacA/B in canine-de-
rived S. aureus isolates, although at lower frequencies than
previously identified in human-derived S. aureus (6% in
U.S.A. MRSP in this study, compared to 8.3–63% previously
described) [56–59]. However, neither qacA/B nor smr ap-
peared related to high chlorhexidine MICs, similar to what
has been described for human-derived S. aureus [38, 41] and
S. epidermidis [60], and in a limited collection of S. pseudin-
termedius [36]. This raises the possibility of different, and as
of yet unknown, mechanisms being responsible for raised
chlorhexidine MICs. Chlorhexidine MICs remained remark-
ably uniform within the same geographical region, repre-
sented by MIC50/MIC90 within one dilution of each other.
Although statistically significant, the difference in the MIC
between some geographical regions was no more than one
to two dilutions, which is unlikely to represent a clinically
significant variation in efficacy of chlorhexidine-based prod-
ucts. The MIC range of chlorhexidine across all geographical
regions tested correlated closely with that previously de-
scribed for S. aureus [37, 38], potentially reflecting relatively
uniform use of chlorhexidine-based products globally in both
human and veterinary medicine.
The increasing interest in the use of topical therapy
for canine pyoderma amidst efforts towards good anti-
microbial stewardship has highlighted the absence of
clinically relevant breakpoints for topically applied
agents, such as fusidic acid and chlorhexidine. The con-
centrations of fusidic acid obtained within the skin 24 h
after application to a canine skin model (of the order of
2000 mg/L) [61], are approximately 1000-fold higher
than the EUCAST breakpoint for fusidic acid for
staphylococci (derived for systemic administration in
humans) [62]. In each of the geographical regions stud-
ied, topical fusidic acid therapy would be expected to
achieve concentrations in canine skin far exceeding the
majority of MICs described in this study [61], despite
presence of resistance determinants in the staphylococ-
cal population tested. These observations highlight the
questionable relevance of routine susceptibility testing
with current conventional protocols when assessing top-
ical treatment options. There is an urgent need for de-
velopment of breakpoints that might usefully predict
antimicrobial efficacy of topically applied drugs in sur-
face and superficial skin infections [63], to prevent the
unwary clinician being misled by laboratory application
of existing breakpoints, developed for systemic therapy,
that leads to reports of ‘resistance’.
Conclusions
Resistance determinants associated with tolerance to
fusidic acid (fusA mutations, fusB and fusC) were de-
tected at a low rate in canine-derived staphylococci in
this study. Conversely, the presence of qacA/B and smr
appeared to have no effect on chlorhexidine MIC. The
low fusidic acid MICs and the lack of fusidic acid resist-
ance determinants in isolates from the U.S.A. compared
to the other geographical regions was not surprising,
given that fusidic acid is not authorised for use in dogs
in the U.S.A. In addition, the overall low prevalence of
resistance genes in this collection of 578 mostly clinical
staphylococcal isolates, and the corresponding low MICs
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for fusidic acid and chlorhexidine, indicate good contin-
ued antibacterial efficacy of these agents. Further clinical
studies to provide good evidence for in vivo efficacy of
these antimicrobials in canine surface and superficial
pyoderma should be encouraged. Further investigations
are now needed to elucidate further the role of fusC,
qacA/B and smr, and to investigate for novel resistance
characteristics that may be of relevance to facilitate fu-
ture resistance monitoring and to guide appropriate use
of these valuable agents.
Methods
Bacterial isolates
A total of 578 coagulase-positive staphylococci (100 S.
aureus obtained in 2005–07 and 478 S. pseudintermedius
obtained in 2010–16) isolated from dogs were included
from four countries: U.K. (split into South-East [SEUK]
and North [NUK] as previously defined) [48], Germany,
Finland and the U.S.A. (Table 5).
All isolates were collected from canine infections (with
the exception of SEUK MSSP, which were both clinical
and carriage isolates) (Table 5). In order to investigate iso-
lates with a wide range of fusidic acid susceptibility, an
extra 40 clinical MRSP from Finland were included
(Finnish FA-R MRSP), which had been determined as fusi-
dic acid-resistant by disk diffusion testing (by MR and
TG) interpreted using the Finnish FiRe criteria (Table 5)
[64, 65]. Species identification and methicillin resistance
were confirmed (by SMF and AL) by both phenotypic [66]
and genotypic methods (for species-specific nuc and
methicillin resistance mecA) [67–69].
MIC determination
Fusidic acid and chlorhexidine MICs were determined in
duplicate using an agar dilution method (CLSI VET01-
A4) [70]. Fusidic acid and chlorhexidine MICs for iso-
lates from SEUK and Germany, and chlorhexidine MICS
for NUK isolates, have been reported previously [48, 49].
Stock solutions of fusidic acid sodium salt (F0881,
Sigma-Aldrich Inc., Gillingham, U.K.) and chlorhexidine
(C9394, Sigma-Aldrich Inc.) at 10 x final concentration,
adjusted for drug potency, were prepared in distilled
water [70]. Final concentrations of the active fraction
ranged from 0.015–64mg/L for fusidic acid and 0.125–
64mg/L for chlorhexidine, based on previous experience
[48, 49]. Discrepancy between the duplicate MICs was
accepted, provided they varied by only one dilution; in
these cases, the higher value was recorded as the final
MIC as a conservative measure. For quality control pur-
poses S. aureus subsp. aureus (ATCC® 25923™), S. pseu-
dintermedius (LMG 22219) and S. intermedius (ATCC®
29663™) were included. Isolates were defined as resistant
or susceptible to fusidic acid using EUCAST breakpoints
[21]; chlorhexidine breakpoints remain unreported.
Identification of resistance genes and mutations
Extraction of DNA was performed using a commercial
purification kit (Bacterial Genomic DNA Purification kit,
Edge BioSystems, Gaithersburg, MD, U.S.A). Each iso-
late’s DNA was screened by PCR for the presence of
fusC [34], fusD [34], qacA/B [71] and smr [72] using
primers and methods as previously described. To detect
fusB, a previously described PCR reaction [55] was opti-
mised by the addition of 1.5 mM MgCl2 to the PCR
mastermix (total 16.5 mM MgCl2).
In isolates with fusidic acid MIC ≥64 mg/L, fusA and
fusE were amplified by PCR and then sequenced using
the Sanger method (Source BioScience, Nottingham,
U.K.) to identify mutations. A previously described
method was used for PCR amplification of fusE [33].
The PCR for amplification of fusA [34] was optimised by
increasing the elongation time from 2 to 3 min. Four for-
ward and four reverse primers, comprising six custom
designed using the S. pseudintermedius ED99 genome se-
quence [35], and two previously described primers [34]
were used for sequencing of the complete gene (Table 3).
Nucleotide and translated amino acid sequences were
aligned to control S. aureus (ATCC® 29663™) and S. (pseu-
d)intermedius (ATCC® 25923™, LMG 22219) fusA / fusE
sequences using EMDL-EBI Clustal Omega Multiple Se-
quence Alignment Tool [73] and BLAST analyses (https://
blast.ncbi.nlm.nih.gov/Blast.cgi).
Table 5 Geographical origin of canine-derived staphylococci used in this study
Geographical location South-East U.K.a North U.K.b Germanyc Finlandd U.S.A.e Total
MRSP 47 49 24 49 50 219
FA-R MRSP 0 0 0 40 0 40
MSSP 44f 50 24 50 51 219
MRSA 50 0 0 0 0 50
MSSA 50 0 0 0 0 50
Total 191 99 48 139 101 578
MRSP methicillin-resistant S. pseudintermedius, FA-R fusidic acid resistant as defined by disk diffusion testing, MSSP methicillin-sensitive S. pseudintermedius, MRSA
methicillin-resistant S. aureus, MSSA methicillin-sensitive S. aureus
All of clinical origin except f which are of clinical (n = 3) and carriage (n = 41) origin
From the authors’ collections: aSMF, RB, AL; bDT; VMS; cAL; dMR, TG; eSCR, KO
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Positive controls for each PCR comprised DNA extracts
from strains carrying the desired genes. These were fusA/
fusE, S. aureus subsp. aureus [ATCC® 25923™] and S. inter-
medius [ATCC® 29663™]; fusB, S. aureus B30 [74]; fusC, S.
aureus MSSA 476 [75]; fusD, S. saprophyticus subsp. sapro-
phyticus [ATCC® 15305™]; qacA/B, S. aureus Mu50 [76];
smr, S. aureus E37 [74]).
Statistical analysis
The MICs (dependent variable) for fusidic acid and
chlorhexidine were compared between MRSP and MSSP
(independent variables) within each geographical region
using the Kruskal-Wallis test. Since MRSP and MSSP
MICs did not vary within any of the regions, S. pseudin-
termedius MICs (dependent variable) were subsequently
compared between regions (independent variable) using
the Kruskal-Wallis tests with post hoc comparisons
using Mann-Whitney U-tests with Holm-Bonferroni ad-
justments. These statistical analyses were performed
using SPSS version 21 (IBM UK Ltd., Portsmouth, U.K.),
with P < 0.05 denoting significance.
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